Last €116.90 EUR
Change Today +0.99 / 0.85%
Volume 0.0
BR6 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 7:53 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BR6) Snapshot

Open
€116.79
Previous Close
€115.91
Day High
€116.93
Day Low
€116.77
52 Week High
10/15/14 - €119.42
52 Week Low
10/23/13 - €91.78
Market Cap
8.7B
Average Volume 10 Days
5.8
EPS TTM
--
Shares Outstanding
74.6M
EX-Date
10/16/14
P/E TM
--
Dividend
€0.87
Dividend Yield
0.55%
Current Stock Chart for CR BARD INC (BR6)

cr bard inc (BR6) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BR6) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular products, including percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. The company’s urology products include Foley catheters to reduce the rate of urinary tract infections; surgical slings to treat stress urinary incontinence; fecal incontinence products; devices for the treatment of pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds to treat prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal; catheter stabilization devices; and products for therapeutic hypothermia. It also provides specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers and other diseases and disorders. In addition, the company offers surgical specialty products, such as implanted grafts and fixation devices for hernia and soft tissue repair products; surgical sealants for intraoperative sealing of air leaks in thoracic surgery; and other products that include irrigation, wound drainage, and original equipment manufacturers’ products. It sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities, as well as through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,000 Employees
Last Reported Date: 02/19/14
Founded in 1907

cr bard inc (BR6) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $540.0K
Group President
Total Annual Compensation: $660.0K
Group President
Total Annual Compensation: $560.0K
Compensation as of Fiscal Year 2013.

cr bard inc (BR6) Key Developments

C. R. Bard, Inc. Announces the U.S. Food and Drug Administration Approval of the Lutonix 035 Drug Coated Balloon Catheter for Percutaneous Transluminal Angioplasty

C. R. Bard Inc. announced the U.S. Food and Drug Administration approval of the Lutonix 035 Drug Coated Balloon Catheter for percutaneous transluminal angioplasty, after pre-dilatation, for the treatment of de novo or restenotic lesions up to 150mm in length in native vascular disease of the superficial femoral or popliteal arteries with reference vessel diameters of 4-6mm. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel in June 2014. The Lutonix 035 DCB--the first and only FDA-approved DCB in the U.S.-- is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries. FDA approval of the Lutonix 035 DCB was supported by results of the LEVANT 2 pivotal study, a global, prospective, single-blind, randomized, 54-site study (42 sites in the U.S. and 12 in Europe) that enrolled all patients under one protocol. At one year, the LEVANT 2 study demonstrated improved patency of the Lutonix 035 DCB compared to standard PTA: 73.5% vs. 56.8%, p<0.001 by Kaplan-Meier time-to-event analysis. It also demonstrated clinical benefits of sustained improvement in Rutherford Class and improved walking distance scores. The LEVANT 2 study followed a rigorous blinding protocol designed to reduce bias in the results to accurately and scientifically assess and compare the long-term performance of key clinical measures. The LEVANT clinical program, which includes registry data, enrolled more than 1,000 patients and demonstrated robust safety of the device comparable to PTA, including the same low rate of distal embolic events and rate of reintervention for thrombotic events.

C. R. Bard, Inc. Declares Quarterly Dividend, Payable on October 31, 2014

The board of directors of C. R. Bard Inc. declared a regular quarterly dividend of 22 cents per share on its common stock. The current indicated annual dividend rate is 88 cents per share. The dividend is payable on October 31, 2014 to shareholders of record at the close of business on October 20, 2014.

CR Bard Inc. to Report Q3, 2014 Results on Oct 22, 2014

CR Bard Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Daylight on Oct 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BR6:GR €116.90 EUR +0.99

BR6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $56.82 USD +0.145
Edwards Lifesciences Corp $105.43 USD -0.38
Endo International PLC $65.03 USD +1.30
Varian Medical Systems Inc $81.77 USD -0.07
View Industry Companies
 

Industry Analysis

BR6

Industry Average

Valuation BR6 Industry Range
Price/Earnings 14.9x
Price/Sales 3.5x
Price/Book 6.5x
Price/Cash Flow 13.9x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.